<DOC>
	<DOC>NCT00252668</DOC>
	<brief_summary>This study is an open label extension of a previously completed double-blind, randomized study comparing etanercept and methotrexate in subjects with active rheumatoid arthritis. All subjects will receive combination treatment with etanercept and methotrexate.</brief_summary>
	<brief_title>Study Evaluating the Combination of Etanercept and Methotrexate in Rheumatoid Arthritis Subjects</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>Subjects who completed the previous doubleblind,randomized study. Ability to reconstitute and selfinject test etanercept (ETN) or have a designee who can do so. Dose of prednisone&gt;10 mg/day (or equivalent) or dose changed within 2 weeks before week 0 evaluation. Clinically relevant concurrent medical events including: uncompensated congestive heart failure (CHF), diagnosis of multiple sclerosis or other central demyelinating diseases, presence or history of confirmed blood dyscrasias, cancer or history of cancer, serious infection within 1 month of test article administration or active infection at week 0.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>Rheumatoid Arthritis</keyword>
</DOC>